Department of Ophthalmology, National Healthcare Group Eye Institute, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Ocul Immunol Inflamm. 2019;27(8):1259-1266. doi: 10.1080/09273948.2018.1517894. Epub 2018 Sep 12.
To analyze the demographic profile, treatment, and visual outcome of the patients with sympathetic ophthalmia (SO) in a multicenter collaborative retrospective cohort study. Medical records of the patients with SO from UK, Singapore, India were reviewed for history of ocular trauma or surgery and subsequent development of uveitis consistent with SO, presenting symptoms, treatment, and visual outcomes. A total of 130 patients were diagnosed with SO during the study period. Eighty-one (62.3%) patients were men. The mean age was 48.4 ± 15.5 years. The most common presenting symptom was blurring of vision (89.2%), followed by pain (29.2%) and floaters (23.8%). Ninety-two (70.7%) required additional immunosuppressive therapy. Thirty-six (27.9%) patients underwent enucleation of the inciting eye. SO is a potentially sight-threatening disease with high rates of visual loss. It warrants prompt evaluation and treatment. With the advances and availability in immunotherapy, the visual prognosis is relatively good.
对多中心合作回顾性队列研究中的交感眼炎 (SO) 患者的人口统计学特征、治疗和视力结果进行分析。对来自英国、新加坡和印度的 SO 患者的病历进行了回顾,以了解眼部创伤或手术史以及随后发生的符合 SO 的葡萄膜炎、出现的症状、治疗和视力结果。在研究期间共诊断出 130 例 SO 患者。81 例(62.3%)为男性。平均年龄为 48.4 ± 15.5 岁。最常见的症状是视力模糊(89.2%),其次是疼痛(29.2%)和飞蚊症(23.8%)。92 例(70.7%)需要额外的免疫抑制治疗。36 例(27.9%)患者行激惹眼眼球摘除术。SO 是一种潜在的致盲性疾病,视力丧失率较高。需要及时评估和治疗。随着免疫治疗的进步和可用性,视力预后相对较好。